Zasti Inc. is proud to announce patent award for its Clinical Trials AI

Zasti

May 1, 2021

Zasti Inc. is excited to announce that the United States Patent and Trademark Office has issued Zasti Inc., it’s patent titled ‘Multimodal Learning Framework for Analysis of Clinical Trials’ (Patent No: US 10971255 B2). The patent can be harnessed for predicting key outcomes in clinical trials.
“This patent award brings transformative customers and partners by enhancing the efficacy of clinical trials to improve patient outcomes in underserved communities”,
-Krish R Krishnan, CEO, Zasti Inc.
This proprietary system for predicting key outcomes in clinical trials can extract information from multiple formats such as Clinical Trials data, Electronic Health Records (EHRs) as well as Computed Tomography (CT) scans.
This patented system will help in the quantitative assessment of the disease and provide an improved predictive model for overall survival metrics. This will also assist clinicians by providing informative cues and serve as a tool for the researchers to perform patient matching for automated and data-driven patient recruitment.
Zasti’s unique Clinical trials AI platform can provide Biotech, Pharma, and CRO companies the ability to accurately predict clinical trial outcomes such as progression of disease and development of adverse reactions, as well as preemptively, identify trials that are likely to fail.
“Estimated cost of bringing a drug to market is at $2.6 billion and on average it takes six to seven years to be market-ready. We believe this patented AI model will help reduce the timeline by increasing the efficiency and efficacy of their clinical trials and also help dramatically cut down the associated carbon footprint”,
-Ram Srinivasan, CSO, Zasti Inc.
This patent award is the first among several AI innovations that showcase Zasti’s technology IP portfolio.
About Zasti
Zasti Inc. is an Advanced Analytics company that offers AI solutions while bringing its strong Environmental, Social, and Governance (ESG) values to US Healthcare. Our AI platforms offer valuable health risk screening and early disease detection for communities in need while creating low carbon pathways for its stakeholders.